Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

81 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients.
Saag M, Balu R, Phillips E, Brachman P, Martorell C, Burman W, Stancil B, Mosteller M, Brothers C, Wannamaker P, Hughes A, Sutherland-Phillips D, Mallal S, Shaefer M; Study of Hypersensitivity to Abacavir and Pharmacogenetic Evaluation Study Team. Saag M, et al. Among authors: shaefer m. Clin Infect Dis. 2008 Apr 1;46(7):1111-8. doi: 10.1086/529382. Clin Infect Dis. 2008. PMID: 18444831 Free article.
New genetic predictors for abacavir tolerance in HLA-B*57:01 positive individuals.
Pavlos R, Deshpande P, Chopra A, Leary S, Strautins K, Nolan D, Thorborn D, Shaefer M, Rauch A, Dunn D, Montaner J, Rachlis A, Almeida CA, Choo L, James I, Redwood AJ, Li Y, Gaudieri S, Mallal SA, Phillips EJ. Pavlos R, et al. Among authors: shaefer m. Hum Immunol. 2020 Jun;81(6):300-304. doi: 10.1016/j.humimm.2020.02.011. Epub 2020 Mar 12. Hum Immunol. 2020. PMID: 32173028 Free PMC article.
Short-term safety and tolerability of a once-daily fixed-dose abacavir-lamivudine combination versus twice-daily dosing of abacavir and lamivudine as separate components: findings from the ALOHA study.
Cohen CJ, Kubota M, Brachman PS, Harley WB, Schneider S, Williams VC, Sutherland-Phillips DH, Lim ML, Balu RB, Shaefer MS; Abacavir-Lamivudine Once-Daily HIV Assessment (ALOHA) Study Group. Cohen CJ, et al. Among authors: shaefer ms. Pharmacotherapy. 2008 Mar;28(3):314-22. doi: 10.1592/phco.28.3.314. Pharmacotherapy. 2008. PMID: 18294111 Clinical Trial.
Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients.
Squires KE, Young B, Dejesus E, Bellos N, Murphy D, Zhao HH, Patel LG, Ross LL, Wannamaker PG, Shaefer MS; ARIES study team. Squires KE, et al. AIDS. 2010 Aug 24;24(13):2019-27. doi: 10.1097/QAD.0b013e32833bee1b. AIDS. 2010. PMID: 20613461 Clinical Trial.
The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial.
Eron J Jr, Yeni P, Gathe J Jr, Estrada V, DeJesus E, Staszewski S, Lackey P, Katlama C, Young B, Yau L, Sutherland-Phillips D, Wannamaker P, Vavro C, Patel L, Yeo J, Shaefer M; KLEAN study team. Eron J Jr, et al. Among authors: shaefer m. Lancet. 2006 Aug 5;368(9534):476-82. doi: 10.1016/S0140-6736(06)69155-1. Lancet. 2006. PMID: 16890834 Clinical Trial.
81 results